Association of inhibitory receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain with immune disorders in chronic HBV infection

Yuxia ZHOU; Caihong WANG; Xiaowen YAO; Rong WANG; Xiaofeng ZHENG; Xiaohui YU; Jiucong ZHANG

doi:10.3969/j.issn.1001-5256.2023.06.026

Volume 39 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(6): 1418-1423

PDF( 2165 KB)

Association of inhibitory receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain with immune disorders in chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2023.06.026

Yuxia ZHOU¹,
Caihong WANG^{1, 2},
Xiaowen YAO¹,
Rong WANG¹,
Xiaofeng ZHENG³,
Xiaohui YU^{2
,
,
,},
Jiucong ZHANG^{2
,
,
,}

1.
The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730030, China
2.
Department of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China
3.
Department of Gastroenterology, The Second Hospital of Lanzhou University, Lanzhou 730030, China

Research funding:

National Natural Science Foundation of China (81500454);

The 940th Hospital Tiptop Project (2021yxky002)

Received Date: 2022-09-30
Accepted Date: 2022-11-11
Published Date: 2023-06-20

Abstract

Abstract

Persistent HBV infection alters the expression of receptors on the surface of innate and acquired immune cells, which may cause a variety of immune disorders and finally lead to immune escape and disease chronicity. Studies have shown that the upregulation of inhibitory receptors is the main cause of immune disorders in patients, and blocking inhibitory receptors can restore immune function to a certain extent. T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a new type of inhibitory receptor attracting much attention at present, and it is highly expressed in NK cells and T cells. It has been found that TIGIT plays an important role in chronic viral infection, and this article briefly reviews the research advances in the association between TIGIT and immune disorders in chronic HBV infection.
- Hepatitis B virus,
- Receptors, Immunologic,
- Immune Disorder

FullText(HTML)

References(31)

References

[1]	MENG Z, CHEN Y, LU M. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection[J]. Front Immunol, 2019, 10: 3127. DOI: 10.3389/fimmu.2019.03127.
[2]	COX MA, NECHANITZKY R, MAK TW. Check point inhibitors as therapies for infectious diseases[J]. Curr Opin Immunol, 2017, 48: 61-67. DOI: 10.1016/j.coi.2017.07.016.
[3]	WANG L, WANG K, ZOU ZQ. Crosstalk between innate and adaptive immunity in hepatitis B virus infection[J]. World J Hepatol, 2015, 7(30): 2980-2991. DOI: 10.4254/wjh.v7.i30.2980.
[4]	HOPCRAFT SE, DAMANIA B. Tumour viruses and innate immunity[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1732): 20160267. DOI: 10.1098/rstb.2016.0267.
[5]	ZHAO HJ, HU YF, HAN QJ, et al. Innate and adaptive immune escape mechanisms of hepatitis B virus[J]. World J Gastroenterol, 2022, 28(9): 881-896. DOI: 10.3748/wjg.v28.i9.881.
[6]	WU J, HAN M, LI J, et al. Immunopathogenesis of HBV infection[J]. Adv Exp Med Biol, 2020, 1179: 71-107. DOI: 10.1007/978-981-13-9151-4_4.
[7]	JIN X, YAN ZH, LU L, et al. Peripheral Immune cells exhaustion and functional impairment in patients with chronic hepatitis B[J]. Front Med (Lausanne), 2021, 8: 759292. DOI: 10.3389/fmed.2021.759292.
[8]	BAUDI I, KAWASHIMA K, ISOGAWA M. HBV-specific CD8⁺ T-cell tolerance in the liver[J]. Front Immunol, 2021, 12: 721975. DOI: 10.3389/fimmu.2021.721975.
[9]	FISICARO P, BARILI V, ROSSI M, et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches[J]. Front Immunol, 2020, 11: 849. DOI: 10.3389/fimmu.2020.00849.
[10]	ROTTE A, SAHASRANAMAN S, BUDHA N. Targeting TIGIT for immunotherapy of cancer: update on clinical development[J]. Biomedicines, 2021, 9(9): 1277. DOI: 10.3390/biomedicines9091277.
[11]	STANIETSKY N, ROVIS TL, GLASNER A, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR[J]. Eur J Immunol, 2013, 43(8): 2138-2150. DOI: 10.1002/eji.201243072.
[12]	JIN HS, PARK Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy[J]. BMB Rep, 2021, 54(1): 2-11. DOI: 10.5483/BMBRep.2021.54.1.229.
[13]	HUANG Z, QI G, MILLER JS, et al. CD226: An emerging role in immunologic diseases[J]. Front Cell Dev Biol, 2020, 8: 564. DOI: 10.3389/fcell.2020.00564.
[14]	HARJUNPÄÄ H, GUILLEREY C. TIGIT as an emerging immune checkpoint[J]. Clin Exp Immunol, 2020, 200(2): 108-119. DOI: 10.1111/cei.13407.
[15]	WANG J, HOU H, MAO L, et al. TIGIT signaling pathway regulates natural killer cell function in chronic hepatitis B virus infection[J]. Front Med (Lausanne), 2021, 8: 816474. DOI: 10.3389/fmed.2021.816474.
[16]	WEI YY, FAN J, SHAN MX, et al. TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection[J]. Am J Transl Res, 2022, 14(2): 942-954.
[17]	LIU C, XU L, XIA C, et al. Increased proportion of functional subpopulations in circulating regulatory T cells in patients with chronic hepatitis B[J]. Hepatol Res, 2020, 50(4): 439-452. DOI: 10.1111/hepr.13472.
[18]	ZHANG W, SUN H, SUN R, et al. HBV immune tolerance of HBs-transgenic mice observed through parabiosis with WT mice[J]. Front Immunol, 2022, 13: 993246. DOI: 10.3389/fimmu.2022.993246.
[19]	LOZANO E, DOMINGUEZ-VILLAR M, KUCHROO V, et al. The TIGIT/CD226 axis regulates human T cell function[J]. J Immunol, 2012, 188(8): 3869-3875. DOI: 10.4049/jimmunol.1103627.
[20]	JIA L, GAO Y, HE Y, et al. HBV induced hepatocellular carcinoma and related potential immunotherapy[J]. Pharmacol Res, 2020, 159: 104992. DOI: 10.1016/j.phrs.2020.104992.
[21]	WU Y, HAO X, WEI H, et al. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice[J]. Hepatology, 2023, 77(3): 965-981. DOI: 10.1002/hep.32715.
[22]	XU F, JIN T, ZHU Y, et al. Immune checkpoint therapy in liver cancer[J]. J Exp Clin Cancer Res, 2018, 37(1): 110. DOI: 10.1186/s13046-018-0777-4.
[23]	LIU X, LI M, WANG X, et al. PD-1⁺ TIGIT⁺ CD8⁺ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2019, 68(12): 2041-2054. DOI: 10.1007/s00262-019-02426-5.
[24]	YU L, LIU X, WANG X, et al. TIGIT⁺ TIM-3⁺ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021, 10(1): 1942673. DOI: 10.1080/2162402X.2021.1942673.
[25]	BLAZKOVA J, HUITING ED, BODDAPATI AK, et al. Correlation between TIGIT expression on CD8⁺ T cells and higher cytotoxic capacity[J]. J Infect Dis, 2021, 224(9): 1599-1604. DOI: 10.1093/infdis/jiab155.
[26]	DUAN X, LIU J, CUI J, et al. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma[J]. Mol Med Rep, 2019, 20(4): 3773-3781. DOI: 10.3892/mmr.2019.10641.
[27]	AMANCHA PK, HONG JJ, ROGERS K, et al. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4⁺ and CD8⁺ T cell responses but has limited clinical benefit[J]. J Immunol, 2013, 191(12): 6060-6070. DOI: 10.4049/jimmunol.1302044.
[28]	FERRANDO-MARTINEZ S, SNELL BENNETT A, LINO E, et al. Functional exhaustion of HBV-specific CD8 T cells impedes pD-L1 blockade efficacy in chronic HBV infection[J]. Front Immunol, 2021, 12: 648420. DOI: 10.3389/fimmu.2021.648420.
[29]	CHEW GM, FUJITA T, WEBB GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection[J]. PLoS Pathog, 2016, 12(1): e1005349. DOI: 10.1371/journal.ppat.1005349.
[30]	GE Z, ZHOU G, CAMPOS CARRASCOSA L, et al. TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8⁺ T cells in hepatocellular carcinoma[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(2): 443-464. DOI: 10.1016/j.jcmgh.2021.03.003.
[31]	ZONG L, PENG H, SUN C, et al. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice[J]. Nat Commun, 2019, 10(1): 221. DOI: 10.1038/s41467-018-08096-8.

Relative Articles

[1]	Linhui HU, Yan WANG. Clinical controversies over antiviral therapy for patients in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2024, 40(5): 875-879. doi: 10.12449/JCH240505
[2]	Xinxin CHEN, Haiping ZHANG, Chunyang HUANG, Jianrong SU, Huiping YAN. Occult HBV infection in autoimmune hepatitis and its influence on disease progression[J]. Journal of Clinical Hepatology, 2022, 38(12): 2738-2743. doi: 10.3969/j.issn.1001-5256.2022.12.011
[3]	Hongyu JIA, Kezhou LIU. Antiviral therapy for patients in the immune-tolerant phase of chronic HBV infection is beneficial for preventing liver cirrhosis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1024-1025. doi: 10.3969/j.issn.1001-5256.2021.05.007
[4]	Bingliang LIN. Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load[J]. Journal of Clinical Hepatology, 2021, 37(4): 778-780. doi: 10.3969/j.issn.1001-5256.2021.04.009
[5]	Yuan HUANG. Patients in the immune-tolerant phase of chronic HBV infection should be actively treated with antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(5): 1026-1026. doi: 10.3969/j.issn.1001-5256.2021.05.008
[6]	Letian LI. Antiviral therapy should be used selectively in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1275-1276. doi: 10.3969/j.issn.1001-5256.2021.06.008
[7]	Deyang WANG, Jun JIANG, Kekai ZHAO. Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(4): 775-776. doi: 10.3969/j.issn.1001-5256.2021.04.007
[8]	Minghui LI, Yao XIE. Antiviral therapy is not recommended for patients in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(4): 783-784. doi: 10.3969/j.issn.1001-5256.2021.04.011
[9]	Jia SHANG. Active antiviral therapy should be given in the immune tolerance stage of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(4): 777-777. doi: 10.3969/j.issn.1001-5256.2021.04.008
[10]	Aiping WANG, Chunyang WEN. Thoughts on recommendations for immune-tolerant phase of chronic hepatitisB virus infection in Guidelines for the management of hepatitis B (version 3.3) released by the Japan Society of Hepatology[J]. Journal of Clinical Hepatology, 2021, 37(7): 1528-1528. doi: 10.3969/j.issn.1001-5256.2021.07.009
[11]	Wei ZHU, Xiaoyong ZHANG, Daqian ZHANG, Jinlin HOU. Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1016-1021. doi: 10.3969/j.issn.1001-5256.2021.05.005
[12]	Min QUAN, Huichun XING. Antiviral therapy is not recommended in immune-tolerant phase chronic hepatitis B patients without complications[J]. Journal of Clinical Hepatology, 2021, 37(6): 1279-1280. doi: 10.3969/j.issn.1001-5256.2021.06.011
[13]	Li XIAO, Jianchun XIAN. Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally[J]. Journal of Clinical Hepatology, 2021, 37(4): 781-782. doi: 10.3969/j.issn.1001-5256.2021.04.010
[14]	Liu XiaoJu, Zhang Zheng. Functional cure of chronic hepatitis B from the perspective of specific immune cells for hepatitis B virus[J]. Journal of Clinical Hepatology, 2020, 36(5): 977-979. doi: 10.3969/j.issn.1001-5256.2020.05.004
[15]	Huang KuiYuan, Liu ZiYing, Zhang XiaoYong. Hepatitis B cured by the activation of intrahepatic innate immunity:Research advances and new strategies[J]. Journal of Clinical Hepatology, 2020, 36(5): 971-976. doi: 10.3969/j.issn.1001-5256.2020.05.003
[16]	Cui FuQiang. Hepatitis B vaccine immunization is the key strategy for prevention of HBV mother-to-child transmission——Comments on 2019 Chinese practice guideline for the prevention and treatment of hepatitis B virus mother-to-child transmission[J]. Journal of Clinical Hepatology, 2020, 36(2): 305-306. doi: 10.3969/j.issn.1001-5256.2020.02.012
[17]	Gao Zhen, Zhang LunLi. Toll like receptors mediated innate immune responses against HBV infection[J]. Journal of Clinical Hepatology, 2011, 27(6): 667-669+673.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (421) PDF downloads(26)

Association of inhibitory receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain with immune disorders in chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2023.06.026

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association of inhibitory receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain with immune disorders in chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2023.06.026

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content